“Whoa! It's like Spotify but for academic articles.”

Instant Access to Thousands of Journals for just $40/month

Get 2 Weeks Free

A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis

1 Introduction</h5> Alzheimer's disease (AD) is a brain disorder named for German physician Alois Alzheimer, who first described it in 1906. Since then, its prevalence rate has increased to 4.5 million individuals ( Hebert et al., 2003 ). It is the most common cause of dementia and the fourth leading cause of death after heart disease, cancer and stroke. Approximately 10% of people over the age of 65 may develop AD ( Kelley and Petersen, 2007 ).</P>Currently there is no definitive cure to stop the progression of the disease, however two types of medications have been approved by the US FDA for treatment of the cognitive symptoms of AD: (i) cholinesterase inhibitors such as rivastigmine (Exelon), donepezil (Aricept), and galantamine (Razadyne) and (ii) glutamate activity regulator, memantine (Namenda) ( Potyk, 2005 ). It is thought that the cognitive impairment in AD results from the deficit or death of neuronal cells, either due to the over activity of enzyme cholinesterase or overexcitation of N-methyl- d -aspartate (NMDA) receptors by the neurotransmitter glutamate.</P>These drugs are commercially available as oral formulations. However, due to a multitude of risk factors in the AD population, such as memory loss and high incidence of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Pharmaceutics Elsevier
Loading next page...

You're reading a free preview. Subscribe to read the entire article.

And millions more from thousands of peer-reviewed journals, for just $40/month

Get 2 Weeks Free

To be the best researcher, you need access to the best research

  • With DeepDyve, you can stop worrying about how much articles cost, or if it's too much hassle to order — it's all at your fingertips. Your research is important and deserves the top content.
  • Read from thousands of the leading scholarly journals from Springer, Elsevier, Nature, IEEE, Wiley-Blackwell and more.
  • All the latest content is available, no embargo periods.